Abstract
This randomised, double-blind, four-way, crossover, Phase II study compared the 24-h forced expiratory volume in 1 s (FEV1) profile of alternative dosing frequencies of two total daily doses of olodaterol (5 and 10 μg) in patients with chronic obstructive pulmonary disease (COPD). Patients received olodaterol 2 μg twice daily (BID), 5 μg BID, 5 μg once daily (QD) and 10 μg QD in a randomised sequence over 3-week treatment periods. Co-primary end points were FEV1 area under the curve from 0 to 12 h (AUC0-12) and area under the curve from 12 to 24 h (AUC12-24) responses. Additional lung-function responses, pharmacokinetics and safety were assessed. 47 patients were treated. All olodaterol doses provided significant increases in FEV1 versus baseline (p < 0.001) and FEV1 time profiles were nearly identical for olodaterol 5 and 10 μg QD. Olodaterol 5 μg QD demonstrated improved FEV1 AUC0-12 and similar AUC12-24 versus 2 μg BID. Olodaterol 5 μg QD showed slightly increased FEV1 AUC0-12 but lower AUC12-24 compared to 5 μg BID. Bronchodilation over 24 h was similar for olodaterol 5 μg QD and BID. All doses were well tolerated. Olodaterol 5 μg QD is efficacious in COPD, with a superior bronchodilatory profile compared to 2 μg BID, which...Continue Reading
References
Apr 24, 2001·American Journal of Respiratory and Critical Care Medicine·R A PauwelsUNKNOWN GOLD Scientific Committee
Feb 5, 2003·Pediatric Pulmonology·Dan Michael Cooper
Jun 29, 2004·The European Respiratory Journal·B R CelliUNKNOWN ATS/ERS Task Force
Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
Jul 19, 2005·Expert Opinion on Investigational Drugs·Mario CazzolaJan Lötvall
Aug 2, 2005·The European Respiratory Journal·M R MillerUNKNOWN ATS/ERS Task Force
Jul 30, 2009·Current Opinion in Allergy and Clinical Immunology·Stefano Guerra
Dec 17, 2009·The Journal of Allergy and Clinical Immunology·Paul M O'ByrneLouis-Philippe Boulet
Apr 8, 2010·The Journal of Pharmacology and Experimental Therapeutics·T BouyssouA Schnapp
Oct 1, 2010·Respiratory Medicine·Edmond L ToyMei Sheng Duh
Aug 16, 2011·Pulmonary Pharmacology & Therapeutics·J A van NoordP J G Cornelissen
Sep 10, 2011·Chest·Rainard FuhrEsther Garcia Gil
Feb 11, 2012·COPD·Edward M KerwinUNKNOWN ACCORD I study investigators
Mar 3, 2012·Chest·Gustavo J Rodrigo, Hugo Neffen
Mar 24, 2012·The European Respiratory Journal·Paul W JonesEsther Garcia Gil
Jun 27, 2014·International Journal of Chronic Obstructive Pulmonary Disease·Gary T FergusonPaul Sachs
Jul 22, 2014·International Journal of Chronic Obstructive Pulmonary Disease·Andrea KochPierluigi Paggiaro
Sep 5, 2014·SpringerPlus·Gregory J FeldmanCraig LaForce
Citations
Aug 19, 2015·Respiratory Research·Paul M O'ByrneKai-Michael Beeh
Jul 17, 2015·Respiratory Research·Kai-Michael BeehMatjaž Fležar
Mar 17, 2015·Drugs·Emma D Deeks
Apr 2, 2015·Respiratory Medicine·M Reza Maleki-YazdiCharles Fogarty
Jul 8, 2016·Respiratory Research·François MaltaisMarc Decramer
Mar 17, 2004·International Journal of Pharmaceutics·Masayo HigashiyamaKakuji Tojo
Oct 13, 2018·Expert Opinion on Pharmacotherapy·Andrea S Melani
Jul 3, 2021·Journal of Clinical Medicine·Shih-Lung Cheng